Celanese (CE) Q4 2025 earnings summary

Executive summary

• Achieved $773M free cash flow in 2025, supporting deleveraging and future growth despite a 7% sales decline and year-over-year earnings drop, with a focus on cost reduction and balance sheet strength.

• Completed key actions including debt refinancing, divestitures (notably Micromax®), and $120M in cost reductions.

• Maintained robust performance in Engineered Materials and Acetyl Chain segments despite soft demand.

• Full year U.S. GAAP diluted loss per share was $(10.44), with adjusted EPS at $3.98, mainly due to $1.6B in impairment charges.

• Strategic focus on free cash flow, sustainable business model changes, and top-line growth.

Financial highlights

• FY2025 operating EBITDA: $1.2B in Engineered Materials, $950M in Acetyl Chain; both segments maintained over 20% EBITDA margin.

• 2025 consolidated operating loss of $786M, adjusted EBIT of $1.2B, and operating EBITDA of $1.9B, with margins of (8)%, 12%, and 20%.

• Q4 2025 free cash flow was $160M; adjusted EPS was $0.67.

• Working capital contributed $390M to free cash flow in 2025; targeting an additional $100M reduction in 2026.

• Lanaken plant closure expected to deliver $20M–$25M in annual cost benefits, with $5M–$10M realized in 2026.

Outlook and guidance

• FY2026 free cash flow guidance is $650M–$750M, achievable even in low-demand scenarios through additional levers.

• Q1 2026 adjusted EPS guidance: $0.70–$0.85; Q1 2026 adjusted EBIT guidance: $210M–$230M for Engineered Materials, $110M–$125M for Acetyl Chain.

• Expecting $1–$2 EPS uplift in 2026 versus 2025, with growth weighted to the second half due to turnaround activity in Q2.

• Demand across most end-markets remains soft entering 2026; ongoing focus on earnings improvement.

• Engineered Materials expected to drive growth, while Acetyl Chain faces more challenges but opportunities for improvement.